Hsien Chung Lin

Dr. Hsien Chung Lin


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2019 in BMC Ophthalmology
Verified
Journal Article
Open access
PDF file
JCJiunn-Liang Chen
Jiunn-Liang Chen
CHChun-Tzu Hung
Chun-Tzu Hung
JKJoseph Jordan Keller
Joseph Jordan Keller
HLHsien Chung Lin
Hsien Chung Lin
WJWu Yu Jen
Wu Yu Jen
Age-related macular degeneration (AMD) is the primary cause of blindness and severe vision loss in developed countries and is responsible for 8.7% of blindness globally. Ultraviolet radiation can induce DNA breakdown, produce reactive oxygen species, and has been implicated as a risk factor for AMD. This study investigated the effects of UVA radiation on Human retinal pigment epithelial cell (ARPE-19) growth and protein expression. ARPE-19 cells were irradiated with a UVA lamp at different doses (5, 10, 20, 30 and 40 J/cm2) from 10 cm. Cell viability was determined by MTT assay. Visual inspection was first achieved with inverted light microscopy and then the DeadEnd™ Fluorometric TUNEL System was used to observe nuclear DNA fragmentation. Flow cytometry based-Annexin V-FITC/PI double-staining was used to further quantify cellular viability. Mitochondrial membrane potential was assessed with JC-1 staining. 2D electrophoresis maps of exposed cells were compared to nonexposed cells and gel images analyzed with PDQuest 2-D Analysis Software. Spots with greater than a 1.5-fold difference were selected for LC-MS/MS analysis and some confirmed by western blot. We further investigated whether caspase activation, apoptotic-related mitochondrial proteins, and regulators of ER stress sensors were involved in UVA-induced apoptosis. We detected 29 differentially expressed proteins (9 up-regulated and 20 down-regulated) in the exposed cells. Some of these proteins such as CALR, GRP78, NPM, Hsp27, PDI, ATP synthase subunit alpha, PRDX1, and GAPDH are associated with anti-proliferation, induction of apoptosis, and oxidative-stress protection. We also detected altered protein expression levels among caspases (caspase 3 and 9) and in the mitochondrial (cytosolic cytochrome C, AIF, Mcl-1, Bcl-2, Bcl-xl, Bax, Bad, and p-Bad) and ER stress-related (p-PERK, p-eIF2α, ATF4 and CHOP) apoptotic pathways. UVA irradiation suppressed the proliferation of ARPE-19 cells in a dose-dependent manner, caused quantitative loses in transmembrane potential (ΔΨm), and induced both early and late apoptosis.

13 September 2019 in Medicina
Verified
Journal Article
Open access
PDF file
WCWei-An Chang
Wei-An Chang
YHYu-Ting Hsiao
Yu-Ting Hsiao
HLHsien Chung Lin
Hsien Chung Lin
SJShu-Fang Jian
Shu-Fang Jian
YCYi-Jen Chen
Yi-Jen Chen
PKPo-Lin Kuo
Po-Lin Kuo
Background and Objectives: Atropine is a nonselective muscarinic antagonist which has been used to prevent worsening of myopia in children. Different concentrations of atropine were used for myopia, ranging from 0.01% to 1.0%. However, there are still potential toxicity of different doses of atropine to the cornea. Here, we present a study of investigating novel genes potentially involved in the effects of very low dose atropine treatment (0.003%) on corneal epithelial cells using next-generation sequencing (NGS) and bioinformatics approaches. Materials and Methods: Human corneal epithelial cells were treated with 0.003% atropine, cultured until confluence, and RNA extracted for differential expression profiling of mRNA and microRNA (miRNA) between control and atropine-treated corneal epithelial cells. The functional enrichment analysis for differentially expressed genes was performed using two bioinformatics databases, including Database for Annotation, Visualization and Integrated Discovery (DAVID) and Ingenuity® Pathway Analysis (IPA). In addition, potential miRNA-mRNA interactions involved in atropine-treated corneal epithelial cells were predicted and validated using different miRNA target prediction databases. Results: Our results showed 0.003% atropine might suppress the apoptosis of corneal epithelial cells, potentially through Ras and protein kinase A signaling pathways. We also validated the possible miRNA regulations by using TargetScan and miRDB databases. Hsa-miR-651-3p-EPHA7, hsa-miR-3148-TMEM108 and hsa-miR-874-5p-TBX6 were validated as possible miRNA regulations involved in corneal epithelial cells treated with 0.003% atropine. Conclusions: These findings may contribute novel insights into therapeutic strategies for treating cornea with 0.003% atropine.

1 December 2015 in Taiwan Journal of Ophthalmology
Verified
Journal Article
Open access
WCWen-Hsin Cheng
Wen-Hsin Cheng
CCCheng-Hsien Chang
Cheng-Hsien Chang
PLPo-Liang Lu
Po-Liang Lu
HLHsien Chung Lin
Hsien Chung Lin
Rifabutin-associated uveitis has been recognized as a dosage-dependent side effect. Previous studies have reported that clarithromycin or fluconazole may elevate concentrations of rifabutin through inhibition of metabolism through the cytochrome P-450 pathway. Nelfinavir is a protease inhibitor widely used in the treatment of human immunodeficiency virus (HIV) infection. The interactions between protease inhibitors and rifabutin have not been reported in clinical practice. Therefore, we present a case of bilateral uveitis associated with coadministration of rifabutin and nelfinavir. Uveitis did not subside until discontinuation of rifabutin. To our knowledge, this is the first report of uveitis with concurrent administration of rifabutin and nelfinavir. Our finding reminds us that rifabutin dosage should be reduced when it is administered with protease inhibitors.

1 September 2023 in Research Square
Verified
Preprint
Open access
PDF file
ICI-Hsien Chen
I-Hsien Chen
HTHung-Ping Tu
Hung-Ping Tu
YCYi-Hsuan Chen
Yi-Hsuan Chen
HLHsien Chung Lin
Hsien Chung Lin
Background To compare the 3-month foveal thickness, sub-foveal choroidal thickness (SFCT) change and best-corrected visual acuity (BCVA) LogMAR response after a sustained release dexamethasone (DEX) intravitreal implant (Ozurdex®) between non-vitrectomized and vitrectomized eyes with diabetic macular edema (DME). Methods Retrospective, comparative, and consecutive review of the medical records of 66 patients with decreased visual acuity, due to refractory DME, who underwent a single and the first injection of Ozurdex® between May 2016 and December 2020 at the teaching hospital of Kaohsiung Medical University. Then, patients were divided into 2 groups: 41 eyes who had undergone standard pars plana vitrectomy (vitrectomized group), and 25 eyes that were not operated on (non-vitrectomized group). Measured outcomes were the change of BCVA LogMAR, foveal thickness, and SFCT from baseline to months 1, 2 and 3. Results Forty-one of 66 eyes had prior vitrectomy (62%). Statistically significant improvement in foveal thickness and SFCT was seen at 1, 2 and 3 months with respect to baseline data, after treatment with a DEX implant in either group (P < 0.0001). There was statistically significant difference in SFCT between non-vitrectomized and vitrectomized eyes at month 3 and the trend from baseline to month 3 (P < 0.0001). Conclusion In this study, the clinical findings were similar between non-vitrectomized and vitrectomized eyes. Intravitreal treatment with an Ozurdex® implant safely reduced DME both in foveal and SFCT in both groups. However, there was statistically significant difference in the trend of SFCT between non-vitrectomized and vitrectomized eyes from baseline to month 3. A DEX implant could be cleared more rapidly in vitrectomized eyes by early detection from SFCT change.